By teaming with Bayer to develop in vitro diagnostics for HIV drug resistance, Amersham Biosciences is hoping to take aim at one-time rival Applied Biosystems in a large and steadily growing market.

The move will also pit Bayer, the No. 3 diagnostic manufacturer, against Abbott Labs, the No. 2 shop, in a largest corner corner of the $50 million HIV-resistance space.

Trouble for Amersham and Bayer is that ABI and corporate kin Celera Diagnostics already have a trio of platforms approved for this indication. Are Bayer and Amersham too far behind?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.